{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae CMV IgM Serum Control Set"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K161526",
    "Predicate Device Reference 510(k) Number(s)": [
        "K040290"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "JJX"
    ],
    "Summary Letter Date": "May 31, 2016",
    "Summary Letter Received Date": "June 02, 2016",
    "Submission Date": "May 31, 2016",
    "Regulation Number(s)": [
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Quality control material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "CMV IgM"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Defibrinated plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae analyzer family"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON CMV IgM Serum Control Set for monitoring the performance of LIAISON CMV IgM assay on LIAISON analyzers",
    "Indications for Use Summary": "Intended for use as assayed quality control samples to monitor the performance of the LIAISON CMV IgM assay on the LIAISON Analyzer family",
    "fda_folder": "Clinical Chemistry"
}